Search

Your search keyword '"Daubert, Jean-Claude"' showing total 28 results
Start Over Author "Daubert, Jean-Claude" Publisher wiley
28 results on '"Daubert, Jean-Claude"'

1. Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality

Author

Shahim, Angiza, primary, Hourqueig, Marion, additional, Lund, Lars H., additional, Savarese, Gianluigi, additional, Oger, Emmanuel, additional, Venkateshvaran, Ashwin, additional, Benson, Lina, additional, Daubert, Jean‐Claude, additional, Linde, Cecilia, additional, Donal, Erwan, additional, and Hage, Camilla, additional

Published
2023
Full Text
View/download PDF

2. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual-patient-data meta-analysis of COMPANION and CARE-HF

Author

Cleland, John G.F., Bristow, Michael R., Freemantle, Nicholas, Olshansk, Brian, Gras, Daniel, Saxon, Leslie, Tavazzi, Luigi, Boehmer, John, Ghio, Stefano, Feldman, Arthur M., Daubert, Jean-Claude, and deMets, David

Abstract

Background: \ud Cardiac resynchronization therapy (CRT) reduces morbidity and mortality for patients with heart failure, reduced left ventricular ejection fraction, QRS duration >130 ms and in sinus rhythm.\ud \ud Objectives: \ud To identify patient-characteristics that predict the effect, specifically, of CRT-pacemakers (CRT-P) on all-cause mortality or the composite of hospitalisation for heart failure or all-cause mortality.\ud \ud Methods: \ud An individual patient-data meta-analysis of the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) and Cardiac Resynchronization – Heart Failure (CARE-HF) trials. Only patients assigned to CRT-P or control (n = 1738) were included in order to avoid confounding from concomitant defibrillator therapy. The influence of baseline characteristics on treatment effects was investigated.\ud \ud Results: \ud Median age was 67 (59–73) years, most patients were men (70%), 68% had a QRS duration of 150-199 ms and 80% had left bundle branch block (LBBB). Patients assigned to CRT-P had lower rates for all-cause mortality (HR 0.68 (95% CI 0.56 to 0.81; p

Published
2022

9. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction

Author

Hai, Ofek Y., primary, Mentz, Robert J., additional, Zannad, Faiez, additional, Gasparini, Maurizio, additional, De Ferrari, Gaetano M., additional, Daubert, Jean‐Claude, additional, Holzmeister, Johannes, additional, Lam, Carolyn S.P., additional, Pochet, Thierry, additional, Vincent, Alphons, additional, and Linde, Cecilia, additional

Published
2014
Full Text
View/download PDF

12. A Randomized Study of Defibrillator Lead Implantations in the Right Ventricular Mid-Septum versus the Apex: The SEPTAL Studyτ

Author

MABO, PHILIPPE, primary, DEFAYE, PASCAL, additional, MOUTON, ELISABETH, additional, CEBRON, JEAN-PIERRE, additional, DAVY, JEAN MARC, additional, TASSIN, AUDE, additional, BABUTY, DOMINIQUE, additional, MONDOLY, PIERRE, additional, PAZIAUD, OLIVIER, additional, ANSELME, FREDERIC, additional, and DAUBERT, JEAN-CLAUDE, additional

Published
2012
Full Text
View/download PDF

13. Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction

Author

Donal, Erwan, primary, Lund, Lars H., additional, Linde, Cecilia, additional, Edner, Magnus, additional, Lafitte, Stéphane, additional, Persson, Hans, additional, Bauer, Fabrice, additional, Öhrvik, John, additional, Ennezat, Pierre-Vladimir, additional, Hage, Camilla, additional, Löfman, Ida, additional, Juilliere, Yves, additional, Logeart, Damien, additional, Derumeaux, Geneviève, additional, Gueret, Pascal, additional, and Daubert, Jean-Claude, additional

Published
2009
Full Text
View/download PDF

22. Preliminary Clinical Experience with the First Dual Chamber Pacemaker Defibrillator

Author

LAVERGNE, THOMAS, primary, DAUBERT, JEAN-CLAUDE, additional, CHAUVIN, MICHEL, additional, DOLLA, ERIC, additional, KACET, SALEM, additional, LEENHARDT, ANTOINE, additional, MABO, PHILIPPE, additional, RITTER, PHILIPPE, additional, SADOUL, NICOLAS, additional, SAOUDI, NADIR, additional, HENRY, CHRISTINE, additional, NITZSCHE, REMI, additional, RIPART, ALAIN, additional, and MURGATROYD, FRANCIS, additional

Published
1997
Full Text
View/download PDF

25. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF.

Author

Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Gras D, Saxon L, Tavazzi L, Boehmer J, Ghio S, Feldman AM, Daubert JC, and de Mets D

Subjects
Adrenergic beta-Antagonists, Aged, Defibrillators, Female, Humans, Male, Morbidity, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Cardiac Resynchronization Therapy methods, Defibrillators, Implantable, Heart Failure epidemiology, Heart Failure therapy
Abstract

Aims: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality for patients with heart failure, reduced left ventricular ejection fraction, QRS duration >130 ms and in sinus rhythm. The aim of this study was to identify patient characteristics that predict the effect, specifically, of CRT pacemakers (CRT-P) on all-cause mortality or the composite of hospitalization for heart failure or all-cause mortality., Methods and Results: We conducted an individual patient data meta-analysis of the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) and Cardiac Resynchronization-Heart Failure (CARE-HF) trials. Only patients assigned to CRT-P or control (n = 1738) were included in order to avoid confounding from concomitant defibrillator therapy. The influence of baseline characteristics on treatment effects was investigated. Median age was 67 (59-73) years, most patients were men (70%), 68% had a QRS duration of 150-199 ms and 80% had left bundle branch block. Patients assigned to CRT-P had lower rates for all-cause mortality (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.56-0.81; p < 0.0001) and the composite outcome (HR 0.67, 95% CI 0.58-0.78; p < 0.0001). No pre-specified characteristic, including sex, aetiology of ventricular dysfunction, QRS duration (within the studied range) or morphology or PR interval significantly influenced the effect of CRT-P on all-cause mortality or the composite outcome. However, CRT-P had a greater effect on the composite outcome for patients with lower body surface area and those prescribed beta-blockers., Conclusions: Cardiac resynchronization therapy-pacemaker reduces morbidity and mortality in appropriately selected patients with heart failure. Benefits may be greater in smaller patients and in those receiving beta-blockers. Neither QRS duration nor morphology independently predicted the benefit of CRT-P., Clinical Trial Registration: COMPANION, NCT00180258; CARE-HF, NCT00170300., (© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2022
Full Text
View/download PDF

26. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction.

Author

Hai OY, Mentz RJ, Zannad F, Gasparini M, De Ferrari GM, Daubert JC, Holzmeister J, Lam CS, Pochet T, Vincent A, and Linde C

Subjects
Humans, Stroke Volume physiology, Cardiac Resynchronization Therapy methods, Heart Failure therapy, Ventricular Dysfunction, Left therapy
Abstract

Cardiac resynchronization therapy is beneficial in heart failure patients with LVEF ≤35% and electrical dyssynchrony. However, its effects among patients with less severe LV dysfunction have not been established. Recent post-hoc analyses of landmark CRT trials suggest that CRT benefit may be present in patients with LVEF >35% and is associated with improvement in cardiac reverse remodelling, all-cause mortality, and need for heart failure hospitalizations. This review summarizes the currently available literature regarding the potential impact of CRT in patients with more modest reductions in LVEF., (© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.)

Published
2015
Full Text
View/download PDF

27. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction.

Author

Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-Löfman I, Ennezat PV, Sportouch-Dukhan C, Drouet E, Daubert JC, and Linde C

Subjects
Aged, Aged, 80 and over, Comorbidity trends, Female, Follow-Up Studies, France epidemiology, Heart Failure physiopathology, Humans, Male, Prognosis, Prospective Studies, Risk Factors, Sweden epidemiology, Time Factors, Heart Failure epidemiology, Heart Valve Diseases epidemiology, Kidney Diseases epidemiology, Lung Diseases epidemiology, Stroke Volume physiology
Abstract

Aims: The prevalence of cardiovascular and non-cardiovascular co-morbidities and their relative importance for outcomes in heart failure with preserved ejection fraction (HFPEF) remain poorly characterized. This study aimed to investigate this., Methods and Results: The Karolinska-Rennes (KaRen) Study was a multinational prospective observational study designed to characterize HFPEF. Inclusion required acute HF, defined by the Framingham criteria, LVEF ≥ 45%, and NT-pro-BNP ≥ 300 ng/L or BNP ≥ 100 ng/L. Detailed clinical data were collected at baseline and patients were followed prospectively for 18 months. Predictors of the primary (HF hospitalization or all-cause mortality) and secondary (all-cause mortality) outcomes were assessed with multivariable Cox regression. A total of 539 patients [56% women; median (interquartile range) age 79 (72-84) years; NT-pro-BNP/BNP 2448 (1290-4790)/429 (229-805) ng/L] were included. Known history of HF was present in 40%. Co-morbidities included hypertension (78%), atrial fibrillation/flutter (65%), anaemia (51%), renal dysfunction (46%), CAD (33%), diabetes (30%), lung disease (25%), and cancer (16%). The primary outcome occurred in 268 patients [50%; 106 deaths (20%) and 162 HF hospitalizations (30%)]. Important independent predictors of the primary and/or secondary outcomes were age, history of non-cardiovascular syncope, valve disease, anaemia, lower sodium, and higher potassium, but no cardiovascular co-morbidities. Renin-angiotensin system antagonist and mineralocorticoid receptor antagonist use predicted improved prognosis., Conclusion: HFPEF was associated with higher age, female gender, hypertension, atrial fibrillation/flutter, and numerous non-cardiovascular co-morbidities. Prognosis was determined by non-cardiovascular co-morbidities, but use of conventional heart failure medications may still be associated with improved outcomes., (© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.)

Published
2014
Full Text
View/download PDF

28. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.

Author

Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, and van Veldhuisen DJ

Subjects
Europe, Evidence-Based Medicine, Exercise Tolerance, Heart Failure classification, Heart Failure physiopathology, Heart-Assist Devices, Humans, Patient Selection, Randomized Controlled Trials as Topic, Societies, Medical, Stroke Volume, Ventricular Remodeling physiology, Cardiac Resynchronization Therapy standards, Defibrillators, Implantable standards, Heart Failure diagnosis, Heart Failure therapy, Pacemaker, Artificial standards
Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results